Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Exelixis posted Q3 2026 total revenues of $658.7 million, up ~10% from $597.8 million a year ago, with U.S. cabozantinib franchise net product revenues of $604.9 million. GAAP diluted EPS was $0.85 versus $0.69 last year, and non-GAAP diluted EPS was $0.94 versus $0.78, helped by buybacks reducing share count. FY2026 revenue guidance was reaffirmed at $2.500-$2.550 billion, with the effective tax rate lowered to 16-18% from 21-23%.
Key figures
- Eps
- 0.85
- Revenue
- 658696000
- Guidance
- FY2026 total revenues $2.500B-$2.550B (unchanged); net product revenues $2.300B-$2.350B (unchanged); effective tax rate lowered to 16-18% from 21-23%; COGS ~4% of net product revenues
- Revenue Yoy
- ~10%
- Gaap net income
- 218095000
- Operating income
- 268423000
- Royalty revenues
- 51800000
- Cumulative buyback
- $3.2 billion, 97.8 million shares at avg $32.25
- Nongaap net income
- 240225000
- Nongaap eps diluted
- 0.94
- Collaboration revenues
- 53772000
- May2026 srp repurchased
- $402.1 million at avg $54.03/share
- Cabozantinib us net product revenue
- 604900000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.